Dewran Kocak and Bryan Roth discuss a psychedelic — 5-MeO-DMT — and what we might learn from its properties.
References
Ross, S. et al. J. Psychopharmacol. 30, 1165–1180 (2016).
Griffiths, R. R. et al. J. Psychopharmacol. 30, 1181–1197 (2016).
McClure-Begley, T. D. & Roth, B. L. Nat. Rev. Drug Discov. 21, 463–473 (2022).
Gribkoff, V. K. & Kaczmarek, L. K. Neuropharmacology 120, 11 (2017).
Willins, D., Deutch, A. & Roth, B. Synapse 27, 79-82 (1997).
Al-Imam, A., Motyka, M. A., Hoffmann, B., Magowska, A. & Michalak, M. Pharmaceuticals 16, 831 (2023).
Reckweg, J. et al. Front. Pharmacol. 12, 760671 (2021).
Phillips, C. A. Copeia 2, 391–393 (2014).
Erspamer, V., Vitali, T., Roseghini, M. & Cei, J. M. Biochem. Pharmacol. 16, 1149–1164 (1967).
Hesselgrave, N., Troppoli, T. A., Wulff, A. B., Cole, A. B. & Thompson, S. M. Proc. Natl Acad. Sci. USA 118, e2022489118 (2021).
Moliner, R. et al. Nat. Neurosci. 26, 1032–1041 (2023).
Kaplan, A. L. et al. Nature 610, 582–591 (2022).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
B.L.R. serves on the Scientific Advisory Boards of Onsero Therapeutics, Escient Pharmaceuticals, Epiodyne Inc. D.D.K. declares no competing interests.
Rights and permissions
About this article
Cite this article
Kocak, D.D., Roth, B.L. Examining psychedelic drug action. Nat. Chem. 16, 142 (2024). https://doi.org/10.1038/s41557-023-01412-w
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41557-023-01412-w
- Springer Nature Limited